Spectrum Pharmaceuticals Appoints Industry Veteran, Former Amgen Executive Joseph Turgeon, as Senior Vice President Sales & Commercial Operations
Mr. Turgeon comes to Spectrum from Amgen where he spent more than
22 years including as VP Sales, Oncology; Joe brings over 25 years of
relevant biotech and pharmaceutical experience
Visionary leader who has built and led sales organizations at Amgen
across multiple areas, including oncology, inflammation and bone health
Proven expert in oncology marketplace; under Mr. Turgeon's
leadership, Amgen Oncology launched four new drugs and revenues rose
from $2 billion to over $6 billion
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced the
appointment of Joseph Turgeon as Senior Vice President Sales &
Commercial Operations. Mr. Turgeon will be responsible for the
commercialization and sales of all Spectrum products; currently,
Spectrum markets FUSILEV® (levoleucovorin) for Injection;
FOLOTYN® (pralatrexate injection); and ZEVALIN®
(ibritumomab tiuxetan) Injection for intravenous use. Mr. Turgeon brings
over 25 years of pharma sales experience, including various executive
leadership roles at Amgen. He will report to Ken Keller, Executive Vice
President and Chief Operating Officer.
"With three anticancer drugs on the market now bringing nearly $300
million in pro forma revenue and nearly ten drugs in clinical
development, we are committed to strong growth in the next five years,"
said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive
Officer of Spectrum Pharmaceuticals, Inc. "The addition of Mr. Turgeon
following appointment of Mr. Keller earlier this year is part of a
planned strategy for expedited growth of Spectrum Pharmaceuticals."
"Having worked with Joe for over twenty years at Amgen, it is my honor
to warmly welcome Mr. Turgeon to Spectrum. His impressive sales record
at Amgen will be a welcome addition as Spectrum continues expanding its
commercial presence on the global market," stated Ken Keller, Executive
Vice President, Chief Operating Officer of Spectrum Pharmaceuticals,
Inc. "Joe's leadership and strategic skills will be broadly beneficial
to Spectrum as we pursue our aggressive international growth plans."
"I am excited to head Spectrum's sales and commercial operations,
especially in light of the recent Allos acquisition, which I believe
represents a strong opportunity for expanding sales. I look forward to
working with the team in this capacity and building on Spectrum's growth
momentum," stated Mr. Turgeon.
Spectrum further announced that due to personal, health reasons, Jim
Shields has decided to retire from the Company, effective immediately.
However, Mr. Shields will continue to serve the organization in an
advisory role. During Mr. Shields' tenure as Chief Commercial Officer,
Spectrum's revenue grew markedly, leading the Company to profitability.
"Jim joined our company in 2010 and immediately provided leadership and
oversight for building our company's dynamic commercial team which
played a critical role in establishing the successful market presence
for FUSILEV and ZEVALIN, our first two commercial products. In addition,
Jim's many contributions helped prepare our company for continued growth
with the recent addition of FOLOTYN to our product portfolio. Jim will
continue to contribute to Spectrum's success as an executive advisor,"
stated Dr. Shrotriya.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary
focus in oncology and hematology. Spectrum and its affiliates market
three oncology drugs - FUSILEV® (levoleucovorin) for
Injection in the U.S.; FOLOTYN® (pralatrexate injection),
also marketed in the U.S.; and ZEVALIN® (ibritumomab
tiuxetan) Injection for intravenous use, for which the Company has
worldwide marketing rights. Spectrum's strong track record in
in-licensing and acquiring differentiated drugs, and expertise in
clinical development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase 3
studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement - This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include but are not limited to statements
that relate to our business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, leveraging the expertise of partners and employees
around the world to assist us in the execution of our strategy, and any
statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical
fact. Risks that could cause actual results to differ include the
possibility that our existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new applications to
the FDA and other regulatory agencies may not receive approval in a
timely manner or at all, the possibility that our existing and new drug
candidates, if approved, may not be more effective, safer or more cost
efficient than competing drugs, the possibility that our efforts to
acquire or in-license and develop additional drug candidates may fail,
our lack of sustained revenue history, our limited marketing experience,
our dependence on third parties for clinical trials, manufacturing,
distribution and quality control and other risks that are described in
further detail in the Company's reports filed with the Securities and
Exchange Commission. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the information
contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.®, FUSILEV®,
FOLOTYN® and ZEVALIN®,
are registered trademarks of Spectrum Pharmaceuticals, Inc and
its affiliates. REDEFINING CANCER CARE™ and the Spectrum
Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals,
© 2012 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
Spectrum Pharmaceuticals, Inc.
Shiv Kapoor, 702-835-6300
President, Strategic Planning & Investor Relations
Source: Spectrum Pharmaceuticals, Inc.
News Provided by Acquire Media
Close window | Back to top